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ABSTRACT 
Background: The benefit that endovascular thrombectomy (EVT) offers to stroke patients 
with large vessel occlusions depends strongly on reperfusion grade as defined by modified 
Thrombolysis in Cerebral Infarction (mTICI) scale. Our aim was to determine the lifetime 
health and cost consequences of reperfusion for patients, healthcare systems, and society. 
Methods: A Markov model estimated lifetime quality-adjusted life years (QALY) and lifetime 
costs of EVT-treated stroke patients based on mTICI grades. The analysis was performed 
over a lifetime horizon in a United States setting adopting healthcare and societal 
perspectives. The reference case analysis was conducted for stroke at 65 years of age. 
National health and cost consequences of improved mTICI 2c/3 reperfusion rates were 
estimated. Input parameters were based on best available evidence.  
Results: Lifetime QALYs increased for every grade of improved reperfusion (median QALYs 
for mTICI 0/1: 2.62; mTICI 2a: 3.46; mTICI 2b: 5.42; mTICI 2c: 5.99; mTICI 3: 6.73). Achieving 
mTICI 3 over mTICI 2b reperfusion resulted on average in 1.31 incremental QALYs as well as 
healthcare and societal cost-savings of $10,327 and $20,224 per patient. A national 10% 
increase in the mTICI 2c/3 reperfusion rate of all annually EVT-treated stroke patients in the 
United States is estimated to yield additional 3,656 QALYs and save $21.0 million and $36.8 
million for the healthcare system and society respectively. 
Conclusions: Improved reperfusion grants stroke patients additional QALYs and leads to 
long-term cost-savings. Procedural strategies to achieve complete reperfusion should be 
assessed for safety and feasibility, even when initial reperfusion seems to be adequate.  
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INTRODUCTION 
Stroke is the leading cause of long-term neurological disability and a frequent cause of death 
worldwide with an annual incidence exceeding 10 million and a prevalence of 42 million.1 
The most detrimental type of ischemic stroke due to large vessel occlusion accounts for just 
one third of its incidence yet represents by far the largest contributor to morbidity and 
mortality.2 Reperfusion by endovascular thrombectomy (EVT) has recently transformed care 
for these patients after seven clinical trials demonstrated substantial benefits in reducing 
disability.3-9 EVT has been adopted as standard of care10 and has been demonstrated to be 
cost-saving in multiple healthcare settings.11-16  
The achieved grade of reperfusion after EVT is critical in this new era of stroke care. The 
current American Stroke Association guidelines recommend mTICI (modified Thrombolysis in 
Cerebral Infarction) grades of 2b or 3 for EVT, with mTICI 2b formerly referring to 50-99% 
reperfusion and mTICI 3 to 100% reperfusion.10 However, as mTICI 2b is very crude, more 
granular definitions were introduced. The mTICI 2c category has been added, which refers to 
90-99% reperfusion. Importantly, every lesser grade of reperfusion has been shown to affect 
neurological outcomes and increase mortality in a meta-analysis of seven trials.17  
The major breakthrough that drove the success of the pivotal EVT trials in 2015 was the 
technical development of third generation thrombectomy devices in the form of stent-
retrievers, which significantly increased reperfusion rates and accelerated procedures.18 To 
evaluate the potential of further improvement of reperfusion, we sought to define and 
quantify the long-term health and cost consequences of the achieved grade of mTICI 
reperfusion for stroke patients, healthcare systems, and society.   
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METHODS 
In support of the Transparency and Openness Promotion Guidelines, the authors offer cost 
calculations for healthcare systems and societies aside from the United States.19 Requests 
that provide a country-specific cost framework are welcomed by the corresponding author. 
 
Model Structure 
We performed quality-adjusted life year (QALY) and cost estimations for the United States 
adopting the healthcare and societal perspective. We adhered to the recommendations by 
the Second Panel on Cost-Effectiveness in Health and Medicine20 and the CHEERS 
(Consolidated Health Economic Evaluation Reporting Standards)21 statement (checklists 
provided in Tables S3 and S4 in the Supplementary Appendix).  
A Markov model was developed using decision-analytic software (TreeAge Pro 2017, version 
17.1.1.0; TreeAge, Williamstown/MA, USA). A short-run model was created to analyze costs 
and functional outcomes within the initial 90 days after the index stroke. Patients enter the 
model on admission to the hospital for acute ischemic stroke with different grades of 
reperfusion after EVT, and afterwards enter one of the seven health states according to the 
degree of disability as assessed by the modified Rankin Scale (mRS). The lead analysis was 
performed for a stroke onset at the age of 65 years. The model does not compare the 
treatments of EVT versus intravenous thrombolysis nor does it apply to patients that only 
receive intravenous thrombolysis. A long-run Markov state transition model estimated the 
expected costs and outcomes over the lifetime of the patient, using a cycle length of one 
year. During each cycle, patients could either remain in the same health state, suffer a 
recurrent stroke and recover or transit to worse mRS states, or die. Death resulted from age-
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related mortality rates and the excess mortality rates of stroke survivors. The model 
structure is shown in Figure 1. All simulations were carried out over a lifetime horizon. 
 
Model Input Parameters 
The input parameters for the model were based on contemporary EVT trial collaboration 
data and the most recently published literature providing the best available level of evidence 
(Table 1).14,22-35 We accounted for the impact of patients' age on all input parameters based 
on a recent systematic review.15  
 
Probabilities of Clinical Events 
The initial probabilities (i.e. the probability of entering a specific mRS health state at the end 
of the initial 90 days) were derived from patients in the intervention arms of the seven EVT 
trials within the HERMES (Highly Effective Reperfusion evaluated in Multiple Endovascular 
Stroke trials) collaboration. The probabilities and 95% confidence intervals for each mRS 
level in the subgroups of mTICI reperfusion grading were calculated after model adjustment 
for age, sex, baseline National Institutes of Health Stroke Scale, and time from symptom 
onset to randomization. The mTICI grades 0 and 1 were merged based on the small sample 
sizes. The transition probabilities during each annual cycle of the long-run model accounted 
for remaining in the same health state, the annual recurrent stroke rate, the probability of 
reentering the same or a lower health state following recurrent stroke, and the annual death 
rate. The age-specific annual death rate of the general population was drawn from the 
United States Life Table.24 The excess death rate of stroke survivors was calculated according 
to hazard rates by mRS health states as reported by contemporary cohort studies.25  
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Costs 
All cost results are divided by the QALYs gained to adjust monetary values to the achieved 
effect. For the healthcare perspective, direct costs within the first 90 days after stroke and 
direct annual long-term costs were based on contemporary data and stratified for each of 
the seven mRS health states.14,26 The costs for EVT were taken from a trial conducted in the 
United States.14 All calculations are based on the assumption that the EVT costs are similar 
for each achieved mTICI grade. The costs for intravenous thrombolysis were taken from the 
current National Inpatient Sample.27 All costs were adjusted to 2017 United States Dollars 
according to the medical care component of the Consumer Price Index35 and discounted by 
3% each year in line with current recommendations.20 For the societal perspective, we 
accounted for indirect costs caused by stroke, which were assessed based on the human 
capital approach. The amount of the societal losses are measured based on the lost 
productivity due to premature mortality in stroke patients, the reduced productivity that is 
caused by the morbidity of stroke survivors, and the costs for informal care given by family 
members.20 The detailed methods for societal cost calculations are provided in the 
Supplementary Appendix. 
 
Utility Values of Health States 
Therapy effectiveness was measured using QALY according to current recommendations.20 
QALYs were calculated by multiplying years spent in mRS health states by assigned utility 
weights. Utility weights were based on a recent consensus analysis.29,36 Values range from 
0.0 to 1.0, with 0.0 representing no, and 1.0 representing perfect quality of life. All QALYs 
were discounted by 3% each year according to current recommendations.20  
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Sensitivity Analyses 
To test the robustness of the model prediction, we conducted probabilistic sensitivity 
analyses, allowing for simultaneous alteration of multiple model input parameters. All input 
values in the model were varied using distributions that reflect each input parameter's 
uncertainty as derived from HERMES collaboration outcome data or the literature. 
Distributions were calculated using probability density functions appropriate to each 
parameter as shown in Table 1 (sensitivity ranges are provided in Table S1 in the 
Supplementary Appendix). The probabilistic sensitivity analysis was conducted using 10,000 
2nd order Monte Carlo simulation runs. As this analysis accounts for all uncertainties related 
to the model, the results are reported as median estimates with 95% prediction intervals. As 
a hypothetical scenario, we additionally performed a one-way sensitivity analysis of the cost-
effectiveness comparing mTICI 3 and mTICI 2b reperfusion by adding excess EVT procedure 
costs to achieve mTICI 3 reperfusion (Figure S3 in the Supplementary Appendix). External 
model validation was performed using one-year longitudinal data as reported by the 
REVASCAT trial37 and two-year longitudinal data as reported by the MR CLEAN trial38 
(Supplementary Methods and Figure S4 in the Supplementary Appendix). 
 
Estimation of Population Level Effects 
For population level effect estimation, the most recently reported annual rate of EVT-treated 
stroke patients in the United States population (3.3% of all 692,000 ischemic strokes) was 
considered to extrapolate patient level results to national estimates.39 We set the mTICI 2c/3 
reperfusion rate within the HERMES meta-analysis as reference and estimated the benefits 
of 10%-step increases.  
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RESULTS 
Reference Case Analysis 
The reference case analysis was conducted over a lifetime horizon for patients suffering a 
large vessel occlusion stroke at 65 years of age. In the probabilistic sensitivity analysis, 
lifetime QALYs increased for every grade of improved reperfusion (median QALYs for mTICI 
0/1: 2.62; mTICI 2a: 3.46; mTICI 2b: 5.42; mTICI 2c: 5.99; mTICI 3: 6.73; Figure 3A). The 
lifetime healthcare and societal costs decreased for every grade of improved reperfusion 
from mTICI 2a to mTICI 3 (e. g. median healthcare costs for mTICI 2a: $249,019; mTICI 2b: 
231,341; mTICI 2c: 225,589; mTICI 3: 220,982; Figure 3B).  
The lifetime costs after mTICI 0/1 reperfusion were slightly higher than after mTICI 3 
reperfusion (Figure 3B), yet on average lower than the other reperfusion grades. This results 
from the considerably shorter life expectancy of stroke patients with mTICI 0/1 reperfusion 
(Figure 3C), by which less costs are accumulated as a consequence. Accounting for costs and 
QALYs simultaneously, the steady increase in the economic outcome measure NMB 
illustrates the additional economic value of care that is provided by each higher grade of 
mTICI reperfusion (Figure 3D). 
The advantage of achieving mTICI 3 over mTICI 2b reperfusion resulted in QALY gains of 1.31 
(95% prediction interval: 0.43-2.12). Based on the sample sizes in the mTICI subgroups, the 
95% prediction intervals of the Monte Carlo simulations are relatively wide, yet on average 
mTICI 3 reperfusion compared to mTICI 2b reperfusion is estimated to save $10,327 and 
$20,224 in healthcare and societal costs per patient treated with EVT (Table 2).  
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The temporal development of cumulative QALYs, functional independence, mortality, 
healthcare and societal costs within the first 20 years after index stroke are provided in 
Figure S2 in the Supplementary Appendix. 
 
Population Level Effect Analysis 
Taking a nationwide perspective, a 10% increase in the mTICI 2c/3 reperfusion rate of all 
annually EVT-treated stroke patients in the United States is estimated to yield additional 
3,656 QALYs and save $21.0 million and $36.8 million for the healthcare system and society 
respectively (Table 3). A 10% increase in the mTICI 2c/3 reperfusion rate would increase the 
economic value of care as measured in the NMB by $387 million and $402 million, taking 
healthcare and societal perspectives respectively. 
 
Sensitivity Analysis 
When comparing mTICI 3 versus mTICI 2b reperfusion, achieving mTICI 3 reperfusion 
remained the cost-saving (i.e. dominant) strategy even if additional procedure costs that 
were needed to hypothetically achieve mTICI 3 after initial mTICI 2b reperfusion amounted 
to $10,000 per patient (Figure S3 in the Supplementary Appendix). Achieving mTICI 3 after 
initial mTICI 2b reperfusion could hypothetically be considered cost-effective even if 
additional procedure costs of $74,000 or $139,000 were incurred, considering contemporary 
willingness-to-pay thresholds of $50,000/QALY or $100,000/QALY respectively. 
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DISCUSSION 
We found that each level of improved reperfusion by EVT in the treatment of stroke patients 
with large vessel occlusions within the first 6 hours of symptom onset had a pronounced 
impact on the patients' lifetime health benefits, the healthcare system, and society. We 
estimated that mTICI 3 over mTICI 2b reperfusion gains patients around 1.3 additional QALYs 
and saves around $10,000 in healthcare and $20,000 in societal costs per patient. If the 
procedure is judged safe and feasible, striving for mTICI 3 reperfusion after initial mTICI 2b 
reperfusion can be supported economically irrespective of any extra procedural costs that 
may potentially be generated along the way. 
Enhanced reperfusion rates largely explain the success of EVT trials published in 2015 as 
compared to the three preceding neutral trials published in 2013, enabled through the stent-
retriever device technology.18 As a consequence of this technical development, the prior 
TIMI (Thrombolysis in Myocardial Infarction) outcome measure was redefined to the 
currently applied mTICI definition.40,41 The recently updated American Stroke Association 
guidelines provide a Level I recommendation that defines procedural success as mTICI 2b or 
mTICI 3 reperfusion.10 Several studies, however, already demonstrated a significant benefit 
of mTICI 3 over mTICI 2b reperfusion.42-44 
In addition, emerging evidence supports a redefinition of the crude mTICI 2b category, which 
encompasses 50-99% reperfusion after EVT.45-47 The subclassification into the mTICI 2c 
reperfusion category clearly related to patients with better functional outcomes.45-47 This 
renewed definition of angiographic success of mTICI 2c and mTICI 3 has already been 
adopted as secondary endpoint in the recently completed ASTER trial on thrombectomy 
technique or the ARISE II trial on thrombectomy devices.48,49 Aside from final reperfusion, 
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the impact of the first pass effect has also been demonstrated to be highly relevant for 
clinical outcomes and should be included in the further testing of new thrombectomy 
devices and techniques.50 
Although oftentimes procedural success is limited by individual circumstances, secondary 
improvement of mTICI 2b to mTICI 2c/3 reperfusion has been reported to be safe and 
feasible.51 Importantly, patients with secondary achievement of mTICI 2c/3 reperfusion 
fared equally well as patients with primary mTICI 2c/3.51 Improved reperfusion leads to 
health benefits and cost-savings as shown in this study. Thus, as the estimated annual 
financial burden of stroke in the United States accumulates to $40 billion52 and is projected 
to triple by 2030,53 further improvement in reperfusion through procedural strategies or 
new devices should be encouraged by interventionalists and by the medical industry.  
How have reperfusion rates improved over recent years and what is the potential in real-
world practice outside of clinical trials? Across all first successful EVT trials of 2015 and 2016, 
the meta-analysis of the HERMES collaboration demonstrated a final reperfusion rate of 
mTICI 2c/3 of 31.4%.17 In the ASTER trial that compared first-line contact aspiration vs. first-
line stent-retriever thrombectomy, the final reperfusion rates of mTICI 2c/3 were already 
56% for both arms.49 In the single-armed ARISE II trial, the final reperfusion of mTICI 2c/3 
was achieved in 76% of patients.48 Single-center experiences outside of clinical trials with 
new EVT techniques even reached final reperfusion mTICI 2c/3 rates of 77 to 80%.54,55  
Therefore, further dissemination of procedural experience, techniques and devices bears 
significant potential to improve the outcome of stroke patients. Given the estimated cost-
savings associated with higher rates of reperfusion in this study, financial investments into 
the training infrastructure, the regional availability of experienced interventionalists and 
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contemporary EVT devices and assist devices (e. g. balloon-guided catheters) appear justified 
as they can be expected to return investment for the healthcare system and society. 
There are limitations of our study that need to be taken into account when interpreting the 
results. First, the cost calculations of the lead analysis were performed under the assumption 
that procedural costs are equal for different mTICI grades. As procedural success is 
influenced by a variety of known and unknown factors that make it difficult to control for, 
we decided to use this unbiased approach to evaluate the implied cost consequences. 
Furthermore, the procedure costs have an overall minor impact on the lifetime financial 
burden of ischemic stroke as shown in sensitivity analysis. Second, the outcome data used 
for model simulations in this study did not arise under the premise of chasing full 
reperfusion if initial reperfusion was adequate. Therefore, safety and feasibility have to be 
addressed in separate studies. Third, the cost calculations were conducted in the United 
States and the absolute amount cannot be converted to other countries. Yet, the overall 
findings of considerable cost-savings associated with improved reperfusion can be assumed 
for other care settings; the authors welcome requests providing country-specific cost 
frameworks and offer calculations of estimated cost-savings for other healthcare systems. 
In conclusion, improved reperfusion after EVT gains QALYs and saves healthcare and societal 
costs. Procedural strategies and device development to achieve highly successful reperfusion 
will be cost-saving and are justified to harness the full potential of EVT for stroke patients 
with large vessel occlusions. 
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FIGURES AND TABLES 
 
Figure 1. Structure of the Simulation Model on Reperfusion Grade after EVT 
Shown is the simulation model used to estimate lifetime costs and quality-adjusted life-years 
of stroke patients with large vessel occlusions depending on the achieved grade of 
reperfusion after endovascular thrombectomy (EVT). Panel A shows subgroups according to 
mTICI grading. The blue square indicates the decision node, the point at which reperfusion is 
decided. In Panel B, the purple encircled letter “M” indicates the Markov node with 
branches indicating the health states in transition each year. In Panel C, the green circle 
indicates the chance node, after which there is a probability of the occurrence of each event 
within a cycle; and the red triangle indicates the terminal node, the end of an individual 
simulation in the model, i.e. the death of a patient. mTICI denotes modified Thrombolysis in 
Cerebral Infarction, EVT endovascular therapy, and mRS modified Rankin Scale. 
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Figure 2. Adjusted 90-Day Clinical Outcome Probabilities Based on HERMES Data 
Shown are the 90-day clinical outcome probabilities of stroke patients in the intervention 
arms of the seven-trial HERMES collaboration stratified by the achieved grade of reperfusion 
after adjustment for age, sex, baseline National Institutes of Health Stroke Scale, and time 
from symptom onset to randomization. The outcomes are scored on the modified Rankin 
Scale, with 0 indicating no residual symptoms after stroke, and 6 indicating death as a cause 
of stroke. mTICI denotes modified Thrombolysis in Cerebral Infarction, and HERMES Highly 
Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials. 
  
0% 20% 40% 60% 80% 100%
mTICI 3
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Score on Modified Rankin Scale at 90 Days
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Figure 3. Estimated Lifetime Health Benefit and Cost-Savings of Successful Reperfusion 
Panel A shows the estimated lifetime QALYs for stroke patients depending on the achieved 
grade of reperfusion. Panel B shows the lifetime healthcare costs and societal costs that 
were achieved per patient. Panel C shows the life expectancy in years. Panel D shows the net 
monetary benefit per patient from healthcare and societal perspectives. The colored bars 
indicate the median values of the simulations, the error bars indicate the 95% prediction 
intervals. mTICI denotes modified Thrombolysis in Cerebral Infarction, and QALY quality-
adjusted life year.  
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Table 1. Base-Case Values and Sources of Model Input Parameters 
    
Model Input Base-Case Value* 
Distributio
n 
Source 
    
Initial Probabilities    
For each health state mRS 0-6  
of EVT-treated patients 
90-day mRS distribution for 
different mTICI grades 
Dirichlet HERMES (Figure 2) 
    
Transition Probabilities    
Recurrent stroke rate 0.059 (for 1st yr) β Pennlert et al.23 
Annual death rate 0.013 (for 65 yrs) β US Life Table 201424 
Annual death hazard rates for  
survivors mRS 0 / 1 / 2 / 3 / 4 / 5 
1.53 / 1.52 / 2.17 /  
3.18 / 4.55 / 6.55 
Log normal Hong et al.25 
After recurrent stroke control arm Dirichlet Goyal et al.22 
    
Health Care Costs    
Costs within first 90 days after stroke 
for mRS 0 / 1 / 2 / 3 / 4 / 5 / 6  
(excluding IVT and EVT) 
$7,996 / $11,038 / $17,336 / 
$21,440 / $28,729 /  
$34,319 / $8,067 
ɣ Dawson et al.26 
Additional cost of IVT treatment $6,961 ɣ NIS 201427 
Additional cost of EVT treatment $14,554 ɣ Shireman et al.14 
Long-term annual costs after stroke  
for mRS 0 / 1 / 2 / 3 / 4 / 5 
$11,245 / $11,579 / $13,395 / 
$23,009 / $46,553 / $68,441 
ɣ Shireman et al.14 
Recurrent stroke hospitalization $23,032 ɣ Chambers et al.28 
    
Utilities    
mRS 0 / 1 / 2 / 3 / 4 / 5 / 6 
1.00 / 0.91 / 0.76 /  
0.65 / 0.33 / 0.00 / 0.00 
β Chaisinanunkul et al.29 
    
Societal Costs    
Paid Workforce Productivity    
Average annual earnings  
of employed population 
$33,000 (for 65 yrs) ɣ US Census Bureau 201730 
Population employment rate 0.312 (for 65 yrs) β 
US Bureau of Labor  
Statistics 201731 
Relative earnings of stroke survivors 0.825 β Vyas et al.32 
Return-to-work after stroke  
mRS 0 / 1 / 2 / 3 / 4 / 5 
0.63 / 0.72 / 0.49 /  
0.19 / 0.14 / 0.00 
β Tanaka et al.33 
    
Unpaid Domestic Productivity    
Informal annual caregiving costs 
mRS 0-1: $1,503 
mRS 2-5: $7,518 
ɣ Hickenbottom et al. 34 
        
All costs were converted to 2017 USD using the medical care component of the Consumer Price Index.35 mTICI denotes modified Thrombolysis in 
Cerebral Infarction, EVT endovascular thrombectomy, HERMES Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials, IVT 
intravenous thrombolysis, mRS modified Rankin Scale, and NIS National Inpatient Sample. 
* The minimum and maximum values for ranges were derived from reported 95% confidence intervals or from calculated 95% confidence 
intervals with the use of variance estimates as available. The complete list is provided in Table S1 in the Supplementary Appendix. 
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Table 2. Lifetime Health and Cost Benefit of Successful Reperfusion 
            
Individual Patient Level Effects (Median Estimates with 95% Prediction Intervals) 
Reperfusion  
Grade 
Δ QALY 
Healthcare Perspective Societal Perspective 
Δ Cost ($) Δ NMB ($) Δ Cost ($) Δ NMB ($) 
      
mTICI 2b Reference* Reference* Reference* Reference* Reference* 
mTICI 2c 
+0.57 
(0.01 to 1.16) 
-5.6K 
(-24K to 12K) 
+63K 
(-5.8K to 131K) 
-9.4K 
(-30K to 10K) 
+68K 
(-4.1K to 137K) 
mTICI 3 
+1.31 
(0.43 to 2.12) 
-10.3K 
(-36K to 15K) 
+142K 
(41K to 234K) 
-20K 
(-48K to 7K) 
+151K  
(49K to 244K) 
            
            
Positive ΔQALY values indicate additional QALYs compared to mTICI 2b. Negative ΔCost 
values indicate cost-savings, positive ΔNMB values indicate higher economic value of care 
compared to mTICI 2b. mTICI denotes modified Thrombolysis in Cerebral Infarction, K 
thousand, NMB net monetary benefit, and QALY quality-adjusted life year.  
*mTICI 2b was set as the reference point for comparisons of mTICI 2c and mTICI 3. mTICI 
2b was selected to reflect the minimum procedural recommendation provided by the 
2018 American Stroke Association guideline. 
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Table 3. National Public Health and Cost Benefits of Successful Reperfusion 
      Annual Population Level Effects in the United States (Median Estimates) 
Rate of mTICI 2c/3 
Reperfusion 
Δ QALY 
Healthcare Perspective Societal Perspective 
Δ Costs ($) Δ NMB ($) Δ Costs ($) Δ NMB ($) 
      31.4% (HERMES) Reference* Reference* Reference* Reference* Reference* 
41.4% (+10%) +3,656 -21.0M +387M -36.8M +402M 
51.4% (+20%) +7,299 -41.8M +772M -73.5M +803M 
61.4% (+30%) +10,941   -62.7M +1,157M -110.2M +1,204M 
71.4% (+40%) +14,583   -84.0M +1,542M -147.0M +1,605M 
81.4% (+50%) +18,225   -104.5M +1,927M -183.7M +2,006M 
            
 
     
Positive ΔQALY values indicate additional QALYs compared to the HERMES rate of mTICI 
2c/3 reperfusion. Negative ΔCost values indicate cost-savings, positive ΔNMB values 
indicate higher economic value of care. HERMES denotes Highly Effective Reperfusion 
across Multiple Endovascular Stroke trials, mTICI modified Thrombolysis in Cerebral 
Infarction, M million, NMB net monetary benefit, and QALY quality-adjusted life year.  
*The reperfusion rate in HERMES was arbitrarily set as the reference point for comparisons. 
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SUPPLEMENTARY METHODS 
Model Structure and Input Parameters for Indirect Cost Calculations 
(references will be added when supplementary appendix in separate document) 
For the societal perspective, we additionally accounted for indirect costs caused by stroke, 
which were assessed based on the human capital approach. The amount of the societal 
losses is measured based on (a) the lost productivity due to premature mortality in stroke 
patients, (b) the reduced productivity that is caused by the morbidity of stroke survivors, and 
(c) the costs for informal care given by family members.  
To analyze the costs caused by premature mortality (a), we used age-dependent productivity 
measures based on nationwide average gross wages of the employed population. Gross 
wage data were available for citizens up to 80 years of age by the United States Census 
Bureau (Current Population Survey); (ref) we assumed complete retirement for all subjects 
older than 80 years. These productivity measures were combined with the general 
population employment status provided by the United States Bureau of Labor Statistics. (ref) 
Non-stroke-related deaths were not considered for premature mortality.  
To model the costs implied by the reduced productivity of stroke survivors (b), we multiplied 
the above-mentioned productivity measures by the relative earnings of stroke survivors 
compared to the non-stroke population (82.5%). (ref) There are no satisfactory data 
available that represent the relative earnings depending on the functional disability as 
measured on the mRS scale. (ref) As there is consensus on the fact that the patient's level of 
disability is the most important predictor of return-to-work (RTW), (ref) we used the 
functional outcome as an alternative approach as previously described. We multiplied each 
above-mentioned productivity measure by the RTW probability of stroke survivors 
27 
 
respective their current level of disability and calculated the difference to the annual 
earnings of a healthy age-matched individual. We used reported RTW probabilities stratified 
by individual mRS health states. (ref)  
The annual costs for informal caregiving (c) were based on estimates for the United States 
and stratified by degrees of disability (mRS 0-1 vs. mRS 2-5). (ref) The hourly wages for home 
health aides in the United States of the year 2017 were used to calculate annual costs. (ref) 
 
External Model Validation 
We validated the model simulations with external data from contemporary EVT trials. The 
only longitudinal data currently available are for a one-year follow-up reported by the 
REVASCAT trial (ref Davalos et al. Lancet Neurol 2017) and for a two-year follow-up reported 
by the MR CLEAN trial (ref van den Berg et al. NEJM 2017). As there are between trial 
differences in outcome distributions within the HERMES collaboration, external model 
validation was performed using the trial-specific 90-day outcomes as applicable to the 
reported longitudinal data. The model simulations matched the reported longitudinal data 
on mortality very well within the available time frames. Given differences among trials, 
overall fair agreement was observed for functional independence and severe disability 
within the available time frames. The results are shown in Figure S4. In addition, we 
compared the lifetime QALY estimates yielded by our model to the reported literature that 
used long-term effectiveness modeling. Overall, despite differences in model structure and 
input variables, the lifetime QALY estimates for EVT-treated patients are well in the range of 
prior cost-effectiveness analyses. An overview is provided in Table S2. 
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Table S1. Detailed Model Input Parameters 
          
Model Input Base-Case Value Distribution Range for Sensitivity Analysis* Reference 
     
Initial Probabilities     
For each health state mRS 0-6  
of EVT-treated patients 
90-day mRS distribution for 
different mTICI grades 
Dirichlet 
adjusted by distribution 
according to sample size 
HERMES Data 
(Figure 2) 
     
Transition Probabilities     
Recurrent stroke rate 0.059 (for 1st yr) β 0.044 - 0.082 Pennlert et al. 
Annual death rate of population 0.013 (for 65 yrs) β N/A US Life Table 2014 
Death hazard rate for mRS 0 1.530 
Log normal 
1.214 - 1.842 
Hong et al. 
Death hazard rate for mRS 1 1.520 1.217 - 1.856 
Death hazard rate for mRS 2 2.170 1.941 - 2.435 
Death hazard rate for mRS 3 3.180 2.851 - 3.641 
Death hazard rate for mRS 4 4.550 4.007 - 5.016 
Death hazard rate for mRS 5 6.550 5.908 - 7.135 
After recurrent stroke control arm Dirichlet 
adjusted by distribution 
according to sample size 
Goyal et al. 
     
Health Care Costs - Acute     
Acute 90 days mRS 0 $7,996 
ɣ 
$6,722 - $9,171 
Dawson et al. 
Acute 90 days mRS 1 $11,038   $9,503 - $12,458 
Acute 90 days mRS 2 $17,336 $15,811 - $19,065 
Acute 90 days mRS 3 $21,440 $19,825 - $23,055 
Acute 90 days mRS 4 $28,729 $26,998 - $30,460 
Acute 90 days mRS 5 $34,319 $31,895 - $36,742 
Acute 90 days mRS 6 $8,067 $7,156 - $9,054 
Additional cost of IVT $6,961 ɣ $4,873 - $9,049 NIS 2014 
Additional cost of EVT $14,554 ɣ $9,518 - $19,590 Shireman et al. 
     
Health Care Costs - Long-term     
Long-term annual mRS 0 $11,245 
ɣ 
  $7,871 - $14,618 
Shireman et al. 
Long-term annual mRS 1 $11,579   $8,105 - $15,053 
Long-term annual mRS 2 $13,395   $9,377 - $17,414 
Long-term annual mRS 3 $23,009 $16,100 - $29,901 
Long-term annual mRS 4 $46,553 $32,587 - $60,519 
Long-term annual mRS 5 $68,441 $47,909 - $88,973 
Recurrent stroke hospitalization $23,032 ɣ $16,123 - $29,942 Chambers et al. 
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Utilities 
mRS 0 1.000 N/A N/A 
Chaisinanunkul et 
al. 
mRS 1 0.910 
β 
0.869 - 0.952 
mRS 2 0.760 0.723 - 0.797 
mRS 3 0.650 0.610 - 0.689 
mRS 4 0.330 0.299 - 0.359 
mRS 5 0.000 0.000 - 0.071 
mRS 6 0.000 N/A N/A 
     
Paid Workforce Productivity    
Average annual earnings of  
employed population 
$33,000 (for 65 yrs) ɣ $23,100 - $42,900 (for 65 yrs) 
US Census  
Bureau 2017 
Population employment rate 0.312 (for 65 yrs) β N/A 
US Bureau of Labor  
Statistics 2017 
Relative earnings of stroke survivors 0.825 β 0.763 - 0.923 Vyas et al. 
Return-to-work after stroke mRS 0 0.630 
β 
0.527 - 0.684 
Tanaka et al. 
Return-to-work after stroke mRS 1 0.720 0.622 - 0.797 
Return-to-work after stroke mRS 2 0.490 0.373 - 0.612 
Return-to-work after stroke mRS 3 0.190 0.089 - 0.353 
Return-to-work after stroke mRS 4 0.140 0.048 - 0.333 
Return-to-work after stroke mRS 5 0.000 N/A N/A 
     
Unpaid Domestic Productivity    
Informal annual caregiving costs 
mRS 0-1: $1,503 
ɣ 
$1,332 - $1,674 
Hickenbottom et al. 
mRS 2-5: $7,518 $6,809 - $8,227 
          
     
All costs were converted to 2017 USD using the medical care component of the Consumer Price Index. mTICI denotes modified Thrombolysis in Cerebral 
Infarction, EVT endovascular thrombectomy, HERMES Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials, IVT intravenous 
thrombolysis, mRS modified Rankin Scale, and NIS National Inpatient Sample. * The minimum and maximum values for ranges were derived from reported 95% 
confidence intervals or from calculated 95% confidence intervals with the use of variance estimates as available.  
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Table S2. Literature-Reported QALY Estimates for Stroke Patients Following Treatment with 
Endovascular Thrombectomy 
      
Reference Country 
Starting 
Age 
Time 
Horizon 
RCT Outcome 
Data Applied 
Cumulative 
QALYs 
      
Shireman et al. Stroke 2017 USA 65 Lifetime SWIFT PRIME 6.79 
Leppert et al. Stroke 2015 USA 65 Lifetime MR CLEAN 3.80 
Ganesalingam et al. Stroke 2015 UK NA 20 HERMES-5 4.84 
Lobotesis et al. J Med Econ 2017 UK 66 Lifetime SWIFT PRIME 7.01 
Campbell et al. Front Neurol 2018 AUS 69 15 EXTEND-IA 7.5 
Aronsson et al. Neurology 2016 SWE 67 Lifetime HERMES-5 2.59 
Steen et al. Int J Stroke 2017 SWE 65 25 HERMES-5 N/A 
Pan et al. BMJ Open 2018 CHN 63 30 HERMES-6* 3.77 
Achit et al. Stroke 2018 FRA 63   1† THRACE   0.58† 
      
This study USA 65 Lifetime HERMES-7* 4.75 
      
QALY denotes quality-adjusted life year, N/A not available, and RCT randomized clinical trial. * HERMES-6 is additionally including 
THRACE, HERMES-7 is additionally including THRACE and PISTE. † This estimate is lower as this study applied a 1-year time horizon.  
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Table S3. Reporting Checklist for Cost-Effectiveness Analyses from the Second Panel on Cost-
Effectiveness in Health and Medicine 
Element 
Journal 
Article 
Technical 
Appendix 
Introduction Page 3  
Background of the problem Page 3  
Study Design and Scope Page 4  
Objectives Page 3  
Audience Page 3  
Type of analysis Page 4  
Target populations Page 4  
Description of interventions and comparators (if applicable) Page 5  
Other intervention descriptors (eg, care setting, model of delivery, intensity and 
timing of intervention) 
Not 
applicable 
 
Boundaries of the analysis; defining the scope or comprehensiveness of the 
study (eg, for a screening program, whether only a subset of many possible 
strategies are included; for interventions with many possible delivery settings, 
whether only one or more settings are modeled) 
Page 5  
Time horizon Page 4  
Analytic perspectives (eg, reference case perspectives [health care sector, 
societal]; other perspectives such as employer or payer) 
Page 4  
Whether this analysis meets the requirements of the reference case Page 4  
Analysis plan Page 7 to 8  
Methods and Data Page 4 to 7 Table S1 
Trial-based analysis or model-based analysis. If model-based: Page 4  
Description of event pathway or model (describe condition and health states) Page 4  
Diagram of event pathway or model (depicting the sequencing and possible 
transitions among the health states included) 
Figure 1 Figure S1 
Description of model used (eg, decision tree, state transition, microsimulation) Page 4 to 5  
Modeling assumptions Page 4 to 8  
Software used Page 4  
Identification of key outcomes Page 7  
Complete information on sources of effectiveness data, cost data, and 
preference weights 
Table 1 Table S1 
Methods for obtaining estimates of effectiveness Page 7  
Methods for obtaining estimates of costs and preference weights Page 5 to 6  
Critique of data quality Page 11  
Statement of costing year (ie, year to which all costs have been adjusted) Page 5  
Statement of method used to adjust costs for inflation Page 5  
Statement of type of currency Page 5  
Source and methods for obtaining expert judgment if applicable 
Not 
applicable 
 
Statement of discount rates Page 5 to 7  
Impact Inventory Page 8  
Full accounting of consequences within and outside the health care sector Page 7 to 8  
Results Page 9  
Results of model validation  Figure S4 
Reference case results (discounted and undiscounted): total costs and Page 9  
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effectiveness, incremental costs and effectiveness, etc. 
Disaggregated results for important categories of costs, outcomes, or both Page 9  
Results of sensitivity analysis Page 9  
Other estimates of uncertainty 
Not 
applicable 
 
Graphical representation of cost-effectiveness results Figure 3  
Graphical representation of uncertainty analyses Figure 3  
Aggregate cost and effectiveness information 
Not 
applicable 
 
Secondary analyses  Figure S2-3 
Disclosures Page 1  
Statement of any potential conflicts of interest due to funding source, 
collaborations, or outside interests 
Page 1  
Discussion Page 11  
Summary of reference case results Page 11  
Summary of sensitivity of results to assumptions and uncertainties  Page 11  
Discussion of the study results in the context of related cost-effective analyses Page 11  
Discussion of ethical implications Page 12  
Limitations of the study Page 12  
Relevance of study results to specific policy questions or decisions Page 12  
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Table S4. Adherence to the CHEERS checklist  
(Items to include when reporting economic evaluations of health interventions) 
Section / Item 
Item 
no. 
Recommendation 
Reported on  
page no. 
Title and abstract 
Title 1 Identify the study as an economic evaluation or 
use more specific terms such as “cost-
effectiveness analysis”, and describe the 
interventions compared. 
Page 1 
Abstract 2 Provide a structured summary of objectives, 
perspective, setting, methods (including study 
design and inputs), results (including base case 
and uncertainty analyses), and conclusions. 
Page 2 
Introduction 
Background and 
objectives 
3 Provide an explicit statement of the broader 
context for the study. 
Page 3 
Present the study question and its relevance for 
health policy or practice decisions. 
Page 3 
Methods 
Target population and 
subgroups 
4 Describe characteristics of the base case 
population and subgroups analyzed, including why 
they were chosen. 
Page 5 
Setting and location 5 State relevant aspects of the system(s) in which 
the decision(s) need(s) to be made. 
Page 4 
Study perspective 6 Describe the perspective of the study and relate 
this to the costs being evaluated. 
Page 4 
Comparators 7 Describe the interventions or strategies being 
compared and state why they were chosen. 
Page 5 
Time horizon 8 State the time horizon(s) over which costs and 
consequences are being evaluated and say why 
appropriate. 
Page 4 
Discount rate 9 Report the choice of discount rate(s) used for 
costs and outcomes and say why appropriate. 
Pages 5 and 7 
Choice of health 
outcomes 
10 Describe what outcomes were used as the 
measure(s) of benefit in the evaluation and their 
relevance for the type of analysis performed. 
Page 7 
Measurement of 
effectiveness 
11a Single study-based estimates: Describe fully the 
design features of the single effectiveness study 
and why the single study was a sufficient source of 
clinical effectiveness data. 
Page 5 
11b Synthesis-based estimates: Describe fully the 
methods used for identification of included 
studies and synthesis of clinical effectiveness data. 
Page 5 
Measurement and 
valuation of preference- 
based outcomes 
12 If applicable, describe the population and 
methods used to elicit preferences for outcomes. 
Not applicable 
Estimating resources and 
costs 
13a Single study-based economic evaluation: Describe 
approaches used to estimate resource use 
associated with the alternative interventions. 
Describe primary or secondary research methods 
for valuing each resource item in terms of its unit 
cost. Describe any adjustments made to 
approximate to opportunity costs. 
Pages 5 to 7 
13b Model-based economic evaluation: Describe 
approaches and data sources used to estimate 
resource use associated with model health states. 
Pages 5 to 7 
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Section / Item 
Item 
no. 
Recommendation 
Reported on  
page no. 
Describe primary or secondary research methods 
for valuing each resource item in terms of its unit 
cost. Describe any adjustments made to 
approximate to opportunity costs. 
Currency, price date, and 
conversion 
14 Report the dates of the estimated resource 
quantities and unit costs. Describe methods for 
adjusting estimated unit costs to the year of 
reported costs if necessary. Describe methods for 
converting costs into a common currency base and 
the exchange rate. 
Page 5 
Choice of model 15 Describe and give reasons for the specific type of 
decision-analytical model used. Providing a figure 
to show model structure is strongly 
recommended. 
Page 4 to 5 
Figure 1 and S1 
 
Assumptions 16 Describe all structural or other assumptions 
underpinning the decision-analytical model. 
Pages 4 to 7 
Analytical methods 17 Describe all analytical methods supporting the 
evaluation. This could include methods for dealing 
with skewed, missing, or censored data; 
extrapolation methods; methods for pooling data; 
approaches to validate or make adjustments (such 
as half cycle corrections) to a model; and methods 
for handling population heterogeneity and 
uncertainty. 
Pages 7 and 8 
Supplementary  
Methods 
Figure S4 
Table S2 
Results 
Study parameters 18 Report the values, ranges, references, and, if used, 
probability distributions for all parameters. Report 
reasons or sources for distributions used to 
represent uncertainty where appropriate. 
Providing a table to show the input values is 
strongly recommended. 
Table 1 and S1 
Incremental costs and 
outcomes 
19 For each intervention, report mean values for the 
main categories of estimated costs and outcomes 
of interest, as well as mean differences between 
the comparator groups. If applicable, report 
incremental cost-effectiveness ratios. 
Page 9 
Figure 3 
Characterizing  
uncertainty 
20a Single study-based economic evaluation: Describe 
the effects of sampling uncertainty for the 
estimated incremental cost and incremental 
effectiveness parameters, together with the 
impact of methodological assumptions (such as 
discount rate, study perspective). 
Page 9 
Figure 3 
20b Model-based economic evaluation: Describe the 
effects on the results of uncertainty for all input 
parameters, and uncertainty related to the 
structure of the model and assumptions. 
Figure S2 
Characterizing 
heterogeneity 
21 If applicable, report differences in costs, 
outcomes, or cost-effectiveness that can be 
explained by variations between subgroups of 
patients with different baseline characteristics or 
other observed variability in effects that are not 
reducible by more information. 
Figure 3 
Figure S2 
Discussion 
Study findings, 
limitations, 
22 Summarize key study findings and describe how 
they support the conclusions reached. Discuss 
Pages 9 to 11 
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Figure S1. Detailed Model Structure 
Shown is the simulation model used to estimate lifetime costs and quality-adjusted life-years 
of stroke patients with large vessel occlusions depending on the achieved grade of 
reperfusion by endovascular thrombectomy (EVT) treatment. The blue square indicates the 
decision node, the point at which the reperfusion is achieved. The purple encircled letter 
“M” indicates the Markov node with branches indicating the health states in transition each 
year. The green circle indicates the chance node, after which there is a probability of the 
occurrence of each event within an annual cycle. The red triangle indicates the terminal 
node, the end of an individual simulation in the model. mTICI denotes modified 
Thrombolysis in Cerebral Infarction, and mRS modified Rankin Scale.  
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Figure S2. Base-Case Projections of QALYs, Functional Independence, Overall Mortality and 
Costs for 20 Years after Stroke Onset Depending on the Achieved Grade of Reperfusion 
Panel A shows the estimated lifetime QALYs for stroke patients depending on the achieved 
grade of reperfusion for the first 20 years after stroke onset. Panel B and C show the 
corresponding percentages of patients remaining functionally independent and the overall 
mortality. Panel D and E show the cumulative healthcare and societal costs. mTICI denotes 
modified Thrombolysis in Cerebral Infarction, and QALY quality-adjusted life year.  
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Figure S3. Cost-Effectiveness Analysis of mTICI 3 vs. mTICI 2b Reperfusion with Simulation of 
Excess EVT Procedure Costs to Achieve mTICI 3 Reperfusion 
Compared are the strategies of mTICI 3 vs. mTICI 2b reperfusion depending on simulated 
excess EVT procedure costs to achieve mTICI 3 reperfusion. Even if an additional $10,000 
would be needed to achieve mTICI 3 over mTICI 2b reperfusion, mTICI 3 remained the 
dominant, i.e. long-term cost-saving strategy. Up to excess procedure costs that accumulate 
to $74,000 and $139,000, mTICI 3 reperfusion was identified as the cost-effective strategy 
applying contemporary WTP thresholds of $50,000/QALY (lower dashed horizontal line) or 
$100,000/QALY (upper dashed horizontal line). mTICI denotes modified Thrombolysis in 
Cerebral Infarction, EVT endovascular thrombectomy, ICER, incremental cost-effectiveness 
ratio, QALY, quality-adjusted life year, and WTP willingness-to-pay. 
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Figure S4. External Validation of Model Simulations 
The figure shows the simulated and observed proportion of subjects with all-cause mortality 
(Panel A), with functional independence (Panel B), and with severe disability (Panel C) within 
a 3-year time frame. The lines indicate the model simulations, the crosses indicate the 
longitudinal trial results as available in the literature. 
